Journal of Antimicrobial Chemotherapy (2000) 46, 41-48
© 2000 The British Society for Antimicrobial Chemotherapy
Effect on the human normal microflora of oral antibiotics for treatment of urinary tract infections
a Department of Microbiology, Pathology and Immunology, Huddinge University Hospital, Karolinska Institute and b Södertörns Högskola, University College, Stockholm, Sweden
Oral administration of antibiotics for treatment of urinary tract infections (UTIs) can cause ecological disturbances in the normal intestinal microflora. Poorly absorbed drugs can reach the colon in active form, suppress susceptible microorganisms and disturb the ecological balance. Suppression of the normal microflora may lead to reduced colonization resistance with subsequent overgrowth of pre-existing, naturally resistant microorganisms, such as yeasts and Clostridium difficile. New colonization by resistant potential pathogens may also occur and may spread within the body or to other patients and cause severe infections. It is therefore important to learn more about the ecological effects of antibacterial agents on the human microflora. The impact on intestinal microorganisms of oral antibiotics used for the treatment of UTIs is reviewed here. Ampicillin, amoxycillin and co-amoxiclav suppress both the aerobic and anaerobic intestinal microflora with overgrowth of ampicillin-resistant Enterobacteriaceae. Pivmecillinam also affects the intestinal microflora, suppressing Escherichia coli, but does not have a major effect on the anaerobic microflora. Several orally administered cephalosporins, such as cefixime, cefpodoxime, cefprozil and ceftibuten, reduce the number of Enterobacteriaceae and increase the number of enterococci. Colonization with C. difficile has also been observed. Fluoroquinolones eliminate or strongly suppress intestinal Enterobacteriaceae, but affect enterococci and anaerobic bacteria only slightly. When antimicrobial agents are prescribed for the treatment of UTIs, not only the antimicrobial spectrum of the agent but also the potential ecological disturbances, including the risk of emergence of resistant strains, should be considered.
* Correspondence address. Department of Microbiology, Pathology and Immunology, F82, Huddinge University Hospital, SE-141 86 Stockholm, Sweden. Tel: +46-8-585-878-38; Fax: +46-8-711-3918; E-mail: carl.erik.nord{at}impi.ki.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A.-M. Tarkkanen, T. Heinonen, R. Jogi, S. Mentula, M. E. van der Rest, C. J. Donskey, T. Kemppainen, K. Gurbanov, and C. E. Nord P1A Recombinant {beta}-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2455 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Maukonen, R. Satokari, J. Matto, H. Soderlund, T. Mattila-Sandholm, and M. Saarela Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J. Med. Microbiol., May 1, 2006; 55(Pt 5): 625 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Norinder, R. Norrby, A.-C. Palmgren, S. Hollenberg, U. Eriksson, and C. E. Nord Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1528 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hay, M. Thomas, A. Montgomery, M. Wetherell, A. Lovering, C. McNulty, D. Lewis, B. Carron, E. Henderson, and A. MacGowan The relationship between primary care antibiotic prescribing and bacterial resistance in adults in the community: a controlled observational study using individual patient data J. Antimicrob. Chemother., July 1, 2005; 56(1): 146 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Putnam, J. W. Sanders, D. R. Tribble, D. R. Rockabrand, M. S. Riddle, P. J. Rozmajzl, and R. W. Frenck Posttreatment Changes in Escherichia coli Antimicrobial Susceptibility Rates among Diarrheic Patients Treated with Ciprofloxacin Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2571 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Trott, L. J. Filippich, J. C. Bensink, M. T. Downs, S. E. McKenzie, K. M. Townsend, S. M. Moss, and J. J.-C. Chin Canine model for investigating the impact of oral enrofloxacin on commensal coliforms and colonization with multidrug-resistant Escherichia coli J. Med. Microbiol., May 1, 2004; 53(5): 439 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Carlsson, M. Govoni, N. P. Wiklund, E. Weitzberg, and J. O. Lundberg In Vitro Evaluation of a New Treatment for Urinary Tract Infections Caused by Nitrate-Reducing Bacteria Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3713 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C R Morris, I M Harvey, W S L Stebbings, C T M Speakman, H J Kennedy, and A R Hart Epidemiology of perforated colonic diverticular disease Postgrad. Med. J., November 1, 2002; 78(925): 654 - 658. [Abstract] [Full Text] [PDF]
|
|